Characterization of hepatitis virus B isolated from a multi-drug refractory patient

Virus Research

Volumn 155, Issue 1, 2011, Pages 254-258

  Wei, Chen ^a   Yu tian, Chong ^a   Ji zhi, Wen ^a   Yong wei, Li ^a   Gang, Li ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Drug resistance; Genome; Hepatitis B virus; Mutation

Indexed keywords

LAMIVUDINE; VIRUS ANTIGEN;

ANTIGEN DETECTION; ARTICLE; GENE AMPLIFICATION; GENOTYPE; HEPATITIS B VIRUS; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STOP CODON; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION;

ADULT; ANTIVIRAL AGENTS; CLONING, MOLECULAR; CLUSTER ANALYSIS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MUTATION, MISSENSE; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIRAL PROTEINS;

HEPATITIS B VIRUS;

EID: 78650539882     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.10.018     Document Type: Article

References (36)

1. Ayres A., Bartholomeusz A., Lau G., Lam K.-C., Lee J.-Y., Locarnini S. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J. Clin. Virol. 2003, 27:111-116.
2. Awan Z., Idrees M., Rafique S., Rehman I-ur, Akbar H., Butt S., Manzoor S., Khan L.A., Munir S., Afzal S., Fatima Z., Rauff B., Naudhani M., Ali M., Saleem S., Badar S. Hepatitis B virus YMDD-motif mutations with emergence of lamivudine-resistant mutants: a threat to recovery. Gastroenterol. Hepatol. Bed Bench 2010, 3:108-114.
3. Angus P., Vaughan R., Xiong S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
4. Benhamou Y., Bochet M., Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999, 30:1302-1306.
5. Bertoletti A., Sette A., Chisari F.V. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994, 369:407-410.
6. Blum H.E. Hepatitis B virus: significance of naturally occurring mutants. Intervirology 1993, 35:40-50.
7. Bock C.T., Tillmann H.L., Torresi J. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002, 122:264-273.
8. Brunelle M.N., Jacquard A.C., Pichoud C. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41:1391-1398.
9. Carman W.F., Jacyna M.R., Hadziyannis S. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989, 2:588-591.
10. Chayama K., Suzuki Y., Kobayashi M. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998, 27:1711-1716.
11. Colonno R.J., Rose R., Baldick C.J. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006, 44:1656-1665.
12. Delaney W.E., Yang H., Westland C.E. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 2003, 77:11833-11841.
13. Domingo E., Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res. 2007, 127:131-150.
14. Durantel D., Brunelle M.-N., Gros E., Carrouée-Durantel S., Pichoud C., Villet S., Trépo C., Zoulim F. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J. Clin. Virol. 2005, 34:S34-S43.
15. Ferrari C., Penna A., Bertoletti A. Cellular immune response to hepatitis B virus-encoded antigen in acute and chronic hepatitis B virus infection. J. Immunol. 1990, 145:3442-3449.
16. Fung S.K., Andreone P., Han S.H. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 2005, 43:937-943.
17. Guo J.J., Li Q.L., Shi X.F. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res. 2009, 81:180-183.
18. Hadziyannis S.J. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin. Investig. Drugs 2007, 16:777-786.
19. Kao J.H., Wu N.H., Chen P.J. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 2000, 33:998-1002.
20. Ling R., Mutimer D., Ahmed M. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996, 24:711-713.
21. Liu C.J., Chen P.J., Lai M.Y. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001, 34:583-589.
22. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J. Hepatol. 2003, 39:S124-S132.
23. Maini M.K., Reignat S., Boni C. T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection. Eur. J. Immunol. 2000, 11:3067-3078.
24. Niesters H.G., De Man R.A., Pas S.D. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J. Med. Microbiol. 2002, 51:695-699.
25. Okamoto H., Tsuda F., Akahane Y. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol. 1994, 68:8102-8110.
26. Omata M., Ehata T., Yokosuka O. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N. Engl. J. Med. 1991, 324:1699-1704.
27. Salfeld J., Pfaff E., Noah M. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J. Virol. 1989, 63:798-808.
28. Shaw T., Bartholomeusz A., Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 2006, 44:593-606.
29. Sheldon J., Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J. Antimicrob. Chemother. 2008, 61:766-768.
30. Shepard C.W., Simard E.P., Finelli L. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 2006, 28:112-125.
31. Tenney D.J., Levine S.M., Rose R.E. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004, 48:3498-3507.
32. Torresi J., Earnest-Silveira L., Civitico G. Restoration of replication phenotype of lamivudineresistant hepatitis B virus mutants by compensatory changes in the " fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002, 299:88-99.
33. Villeneuve J.P., Durantel D., Durantel S. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 2003, 39:1085-1089.
34. Wang J.H., Lu S.N., Lee C.M. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand. J. Gastroenterol. 2002, 37:366-369.
35. WHO, 2010, fact sheet: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
36. Zhang Q., Wu G., Richards E. Universal primers for HBV genome DNA amplification across subtypes: a case study for designing more effective viral primers. Virol. J. 2007, 24:92.